<DOC>
	<DOCNO>NCT00370006</DOCNO>
	<brief_summary>Objectives trial : 1 . Evaluate kinetics magnitude CMV-specific immune response post-Towne challenge ( 3000 pfu ) healthy CMV-seronegative volunteer receive VCL CT02 administer ID IM 9 15 month previously measure : 1 ) ELISA and/or virus-neutralizing antibody titer gB ; 2 ) T-cell IFN-g ELISPOT ; 3 ) T-cell proliferation assay ( CFSE ) IE1 , pp65 , and/or gB ; possibly 4 ) cytokine phenotypic flow cytometry response pp65 , IE1 , and/or gB . 2 . Evaluate safety safety Towne challenge healthy CMV-seronegative adult subject previously immunize trivalent pDNA CMV vaccine ( VCL-CT02 ) administer intramuscularly ( IM ) intradermally ( ID ) . Our hypothesis immune response Towne vaccine 3000 pfu challenge VLC-CT02 priming great Towne vaccination alone ( concurrent control administer Towne alone concurrent , companion trial ) .</brief_summary>
	<brief_title>Phase 1 Trial CMV Towne Vaccine Subjects Previously Received VCL CT02 Vaccine ID IM</brief_title>
	<detailed_description>This Phase 1 , single-center , open-label trial live , attenuate Towne CMV vaccine administer “ challenge ” healthy , CMV-seronegative , adult subject previously receive CMV immunotherapeutic trivalent pDNA-based vaccine , VCL-CT02 , give intradermal intramuscular route describe follow table ; subject follow 32 week . Table 6.1 Subject Distribution Group Formulation Dosing Regimen ( day ) Dose per Injection ( Administered deltoid region ) Route Administration Number Subjects 1 . VCL-CT02 0 , 28 , 56 1.0 mg Intramuscular ( IM ) 6 2 . VCL-CT02 0 , 28 , 56 100 μg/injection × 2 injection Intradermal ( ID ) 11 Total 17 Up 10 subject Groups 1 2 approached enrollment current protocol . If subject consent meet eligibility criterion , subject receive Towne ( 3000 pfu subcutaneously ) 9 15 month subject ’ first dose VCL-CT02 . Safety monitor Both antibody CMV gB T-cell response CMV antigen measure specified interval 252 day post Towne challenge .</detailed_description>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>18 45 year age time initial enrollment trial CT02ID ; normal lab value study entry ; good general health ; CMV IgG antibody test &lt; 4 time last measured value ( i.e. , Week 32 VCLCT02 administration CT02ID initiate ) CMV seropositive ; recent vaccination ( ) ; immunodeficiency ; vaccination investigational CMV vaccine ( ) VCLCT02 ; pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>cytomegalovirus</keyword>
	<keyword>vaccine</keyword>
	<keyword>T cell</keyword>
	<keyword>antibody</keyword>
</DOC>